Use of A33 antigens and JAM-IT

A method of treating an inflammatory disorder in a mammal comprising administering a therapeutically effective amount of a PRO362 antagonist.

A method of treating an inflammatory disorder in a mammal comprising administering a therapeutically effective amount of a PRO245 antagonist.

A method of diagnosing an inflammatory disorder in a mammal, said method comprising detecting the level of expression of a gene encoding a PRO362 or PRO245 polypeptide (a) in a test sample of cells obtained from said mammal, and (b) in a control sample of known normal cells of the same cell type, wherein a higher level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of an immune related disorder in the mammal from which the test tissue cells were obtained.

A method of diagnosing an inflammatory disorder in a mammal, said method comprising (a) contacting an anti-PRO362 or anti-PRO3245 with a test sample of cells obtained from said mammal, and (b) detecting the formation of a complex between the antibody and PRO362 or PRO245 polypeptide in the test sample, wherein formation of said complex is indicative of the presence of an inflammatory disorder in said mammal.

A method for detecting the presence of a tumor in a mammal, said method comprising comparing the level of expression of a gene encoding a PRO301, PRO362, PRO245 or PRO1868 polypeptide (a) in a test sample of cells taken from said mammal, and (b) in a control sample of known normal cells of the same cell type, wherein a higher expression level of said polypeptide in the test sample as compared to the control sample is indicative of the presence of tumor in the mammal.

A method of diagnosing tumor in a mammal, said method comprising (a) contacting an antibody selected from the group consisting of an anti-PRO301 antibody, an anti-PRO362 antibody, an anti-PRO245 antibody and an anti-PRO1868 antibody with a test sample of cells obtained from said mammal, and (b) detecting the formation of a complex between the anti-PRO301, anti-PRO362, anti-PRO245 or anti-PRO1868 antibody and a PRO301, PRO362, PRO245 or PRO1868 polypeptide, respectively, in the test sample, wherein the formation of a complex is indicative of the presence of a tumor in the mammal.

An isolated antibody which specifically binds a PRO301, PRO362, PRO245 or PRO1868 polypeptide.

Isolated nucleic acid comprising DNA having at least 80% sequence identity to (a) a DNA molecule encoding a PRO1868 polypeptide comprising the sequence of amino acid residues 1 to 310 of FIG. 22 (SEQ ID NO:

• 31), or (b) the complement of the DNA molecule of (a).

Isolated nucleic acid having at least 80% nucleic acid sequence identity to the full-length coding sequence of the cDNA deposited under ATCC accession number 203553.

Isolated native sequence PRO1868 polypeptide comprising amino acid residues 1 to 310 of FIG. 22 (SEQ ID NO:

• 31).

Isolated PRO1868 polypeptide comprising amino acids 1 to X of the amino acid sequence shown in FIG. 22 (SEQ ID NO:

• 31), wherein X is any one or amino acids 237 to 247.

An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence encoded by the full-length coding sequence of the cDNA depsoited under ATCC accession number 203553.